Compare NP & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | CRSP |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | Switzerland |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | N/A | 2016 |
| Metric | NP | CRSP |
|---|---|---|
| Price | $31.48 | $48.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $28.17 | ★ $70.29 |
| AVG Volume (30 Days) | 936.6K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $25.84 | $807.72 |
| Revenue Next Year | $15.80 | $172.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $14.78 | $44.12 |
| 52 Week High | $34.61 | $78.48 |
| Indicator | NP | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 37.70 |
| Support Level | $23.62 | $47.48 |
| Resistance Level | $31.63 | $59.61 |
| Average True Range (ATR) | 1.53 | 3.29 |
| MACD | -0.24 | -1.11 |
| Stochastic Oscillator | 40.72 | 7.76 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.